Reducing intraocular pressure: Is surgery better than drugs?

Eye

Volumn 18, Issue 12, 2004, Pages 1215-1224

  Shaarawy, T ^a,b   Flammer, J ^b   Haefliger, I O ^b  

^a Institute of Ophthalmology   (Egypt)

^b UNIVERSITY EYE CLINIC   (Switzerland)

Author keywords

Deep sclerectomy; Glaucoma; Intraocular pressure; Non penetrating; Trabeculectomy; Viscocanalostomy

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIHYPERTENSIVE AGENT; ANTIMETABOLITE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAXOLOL; CARBONATE DEHYDRATASE INHIBITOR; CHOLINERGIC RECEPTOR STIMULATING AGENT; DORZOLAMIDE; FLUOROURACIL; LATANOPROST; MITOMYCIN C; PROSTAGLANDIN; TIMOLOL;

ARTICLE; BLOOD DYSCRASIA; BRADYCARDIA; CATARACT; CIRCADIAN RHYTHM; CLINICAL TRIAL; CONFUSION; COST BENEFIT ANALYSIS; DEPRESSION; DYSPNEA; EVIDENCE BASED MEDICINE; FATIGUE; FILTERING OPERATION; GASTROINTESTINAL SYMPTOM; GLAUCOMA; GLAUCOMA SURGERY; HEADACHE; HEART PALPITATION; HUMAN; HYPOKALEMIA; HYPOTENSION; IMPOTENCE; INTRAOCULAR PRESSURE; LIBIDO DISORDER; LONG TERM CARE; NAUSEA AND VOMITING; NEPHROLITHIASIS; PARESTHESIA; PATIENT COMPLIANCE; PERIPHERAL VASCULAR DISEASE; POLYURIA; RASH; REDUCTION; RESPIRATORY ARREST; SYSTEMATIC REVIEW; TRABECULECTOMY; XEROSTOMIA;

EID: 11844287553     PISSN: 0950222X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.eye.6701374     Document Type: Article

References (110)

1. Anderson DR. Glaucoma: the damage caused by pressure. XLVI Edward Jackson memorial lecture. Am J Ophthalmol 1989; 108: 485-495.
2. Bathija R, Gupta N, Zangwill L, Weinreb RN. Changing definition of glaucoma. J Glaucoma 1998; 7: 165-169.
3. Foster PJ, Buhrmann R, Quigley HA, Johnson GJ. The definition and classification of glaucoma in prevalence surveys. Br J Ophthalmol 2002; 86: 238-242.
4. Munoz B, West SK, Rubin GS, Schein OD, Quigley HA, Bressler SB et al. Causes of blindness and visual impairment in a population of older Americans: The Salisbury Eye Evaluation Study. Arch Ophthalmol 2000; 118: 819-825.
5. Quigley HA, Vitale S. Models of open-angle glaucoma prevalence and incidence in the United States. Invest Ophthalmol Vis Sci 1997; 38: 83-91.
6. Quigley HA. Proportion of those with open-angle glaucoma who become blind. Ophthalmology 1999; 106: 2039-2041.
7. Buckley C, Hadoke PW, Henry E, O'Brien C. Systemic vascular endothelial cell dysfunction in normal pressure glaucoma. Br J Ophthalmol 2002; 86: 227-232.
8. Gasser P. Why study vascular factors in glaucoma? Int Ophthalmol 1998; 22: 221-225.
9. Haefliger IO, Dettmann E, Liu R, Meyer P, Prunte C, Messerli J et al. Potential role of nitric oxide and endothelin in the pathogenesis of glaucoma. Surv Ophthalmol 1999; 43(Suppl 1 : S51-S58.
10. Leske MC, Heijl A, Hussein M, Bengtsson B, Hyman L, Komaroff E. Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch Ophthalmol 2003; 121: 48-56.
11. Osborne NN, Chidlow G, Nash MS, Wood JP. The potential of neuroprotection in glaucoma treatment. Curr Opin Ophthalmol 1999; 10: 82-92.
12. Palmberg P. Risk factors for glaucoma progression: Where does intraocular pressure fit in? Arch Ophthalmol 2001; 119: 897-898.
13. Ritch R. Exfoliation syndrome. Curr Opin Ophthalmol 2001; 12: 124-130.
14. Soltau JB, Zimmerman TJ. Changing paradigms in the medical treatment of glaucoma. Surv Ophthalmol 2002; 47 (Suppl): S2-S5.
15. Leske MC, Heijl A, Hussein M, Bengtsson B, Hyman L, Komaroff E. Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trail. Arch Ophthalmol 2003; 121(1 : 48-56.
16. Leske MC, Heijl A, Hussein M, Bengtsson B, Hyman L, Komaroff E. Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch Ophthalmol 2003; 121: 48-56.
17. Collaborative Normal-Tension Glaucoma Study Group. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am J Ophthalmol 1998; 126: 498-505.
18. Bron A. Treatment of glaucomas. Rev Prat 2001; 51 2198-2201.
19. Hedman K, Watson PG, Alm A. The effect of latanoprost on intraocular pressure during 2 years of treatment. Surv Ophthalmol 2002; 47 (Suppl 1): S65-S76.
20. Rothman RF, Liebmann JM, Ritch R. Low-dose 5-fluorouracil trabeculectomy as initial surgery in uncomplicated glaucoma: long-term followup. Ophthalmology 2000; 107 (Suppl 6): 1184-1190.
21. Uchida S, Suzuki Y, Araie M, Shigeeda T, Hara T, Shirato S. Long-term follow-up of initial 5-fluorouracil trabeculectomy in primary open-angle glaucoma in Japanese patients. J Glaucoma 2001; 10 (Suppl 6): 458-465.
22. Wilensky JT. The role of medical therapy in the rank order of glaucoma treatment. Curr Opin Ophthalmol 1999; 10: 109-111.
23. Shaarawy T. Surgery for glaucoma in the 21st century. Br J Ophthalmol 2003; 87: 250.
24. Janz NK, Wren PA, Lichter PR, Musch DC, Gillespie BW, Guire KE et al. The Collaborative Initial Glaucoma Treatment Study: interim quality of life findings after initial medical or surgical treatment of glaucoma. Ophthalmology 2001; 108: 1954-1965.
25. Ritch R. Initial treatment of exfoliative glaucoma. J Glaucoma 1998; 7: 137-140.
26. Hitchings R. Initial treatment for open-angle glaucoma - medical, laser, or surgical? Surgery is the treatment of choice for open-angle glaucoma. Arch Ophthalmol 1998; 116: 241-242.
27. Jampel HD. Initial treatment for open-angle glaucoma - medical laser, or surgical? Laser trabeculoplasty is the treatment of choice for chronic open-angle glaucoma. Arch Ophthalmol 1998; 116: 240-241.
28. Higginbotham EJ. Initial treatment for open-angle glaucoma - medical, laser or surgical? Medication is the treatment of choice for chronic open-angle glaucoma. Arch Ophthalmol 1998; 116: 239-240.
29. Pliushko DG. Drug treatment of the initial stage of glaucoma. Oftalmol Zh 1981; 36: 4-8.
30. Khaw PT, Cordeiro MF, Cordiero MF. Towards better treatment of glaucoma. Br Med J 2000; 320: 1619-1620.
31. Rouland JF, Le Pen C, Gouveia PC, Berto P, Berdeaux G. Cost-minimisation study of dorzolamide versus brinzolamide in the treatment of ocular hypertension and primary open-angle glaucoma: in four European countries. Pharmacoeconomics 2003; 21: 201-213.
32. Ogawa T, Ogawa A, So K. Target intraocular pressure and risk factors for progression of visual field loss in primary open-angle glaucoma. Nippon Ganka Gakkai Zasshi 2002; 106: 488-493.
33. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. The AGIS Investigators. Am J Ophthalmol 2000; 130 429-440.
34. Briggs MC, Jay JL. Age over 46 years does not affect the pressure lowering effect of trabeculectomy in primary open angle glaucoma. Br J Ophthalmol 1999; 83: 280-284.
35. Ustundag C, Diestelhorst M. Effect of mitomycin C on aqueous humor flow, flare and intraocular pressure in eyes with glaucoma 2 years after trabeculectomy. Graefes Arch Clin Exp Ophthalmol 1998; 236 734-738.
36. Wilson RP, Steinmann WC. Use of trabeculectomy with postoperative 5-fluorouracil in patients requiring extremely low intraocular pressure levels to limit further glaucoma progression. Ophthalmology 1991; 98: 1047-1052.
37. Saiz A, Alcuaz A, Maquet JA, de la Fuente F. Pressure-curve variations after trabeculectomy for chronic primary open-angle glaucoma. Ophthalmic Surg 1990; 21 (Suppl 11): 799-801.
38. Migdal C, Gregory W, Hitchings R. Long-term functional outcome after early surgery compared with laser and medicine in open-angle glaucoma. Ophthalmology 1994; 101: 1651-1656.
39. Watson PG, Barnett MF, Parker V, Haybittle J. A 7 year prospective comparative study of three topical beta blockers in the management of primary open angle glaucoma. Br J Ophthalmol 2001; 85: 962-968.
40. Watson PG. Latanoprost. Two years' experience of its use in the United Kingdom. Latanoprost Study Group. Ophthalmology 1998; 105: 82-87.
41. AIm A, Camras CB, Watson PG. Phase III latanoprost studies in Scandinavia, the United Kingdom and the United States. Surv Ophthalmol 1997; 41(Suppl 2): S105-S110.
42. Chen TC, Wilensky JT, Viana MA. Long-term follow-up of initially successful trabeculectomy. Ophthalmology 1997; 104: 1120-1125.
43. Suzuki R, Dickens CJ, Iwach AG, Hoskins Jr HD, Hetherington Jr J, Juster RP et al. Long-term follow-up of initially successful trabeculectomy with 5-fluorouracil injections. Ophthalmology 2002; 109: 1921-1924.
44. Niesel P, Flammer J. Correlations between intraocular pressure, visual field and visual acuity, based on 11 years of observations of treated chronic glaucomas. Int Ophthalmol 1980; 3: 31-35.
45. Flammer J, Eppler E, Niesel P. Quantitative perimetry in the glaucoma patient without local visual field defects. Graefes Arch Clin Exp Ophthalmol 1982; 219: 92-94.
46. Asrani S, Zeimer R, Wilensky J, Gieser D, Vitale S, Lindenmuth K. Large diurnal fluctuations in intraocular pressure are an independent risk factor in patients with glaucoma. J Glaucoma 2000; 9: 134-142.
47. Medeiros FA, Pinheiro A, Moura FC, Leal BC, Susanna R Jr. Intraocular pressure fluctuations in medical versus surgically treated glaucomatous patients. J Ocul Pharmacol Ther 2002; 18: 489-498.
48. Orzalesi N, Rossetti I, Bottoli A, Invernizzi T, Fumagalli E, Fogagnolo P. Comparison of latanoprost, brimonidine and a fixed combination of timolol and dorzolamide on circadian intraocular pressure in patients with primary open-angle glaucoma and ocular hypertension. Acta Ophthalmol Scand Suppl 2002; 236: 55.
49. Norell S. Medication behaviour. A study of outpatients treated with pilocarpine eye drops for primary open-angle glaucoma. Acta Ophthalmol Suppl 1980; (Suppl 143): 1-28.
50. Norell SE. Improving medication compliance: a randomised clinical trial. Br Med J 1979; 2: 1031-1033.
51. Kosoko O, Quigley HA, Vitale S, Enger C, Kerrigan L, Tielsch JM. Risk factors for noncompliance with glaucoma follow-up visits in a residents' eye clinic. Ophthalmology 1998; 105: 2105-2111.
52. Rotchford AP, Murphy KM. Compliance with timolol treatment in glaucoma. Eye 1998; 12(Part 2): 234-236.
53. Fingeret M, Schuettenberg SP. Patient drug schedules and compliance. J Am Optom Assoc 1991; 62: 478-480.
54. Granstrom PA. Progression of visual field defects in glaucoma. Relation to compliance with pilocarpine therapy. Arch Ophthalmol 1985; 103: 529-531.
55. Norell SE. Improving medication compliance: a randomised clinical trial. Br Med J 1979; 2: 1031-1033.
56. Konstas AG, Maskaleris G, Gratsonidis S, Sardelli C. Compliance and viewpoint of glaucoma patients in Greece. Eye 2000; 14(Part 5): 752-756.
57. Patel SC, Spaeth GL. Compliance in patients prescribed eyedrops for glaucoma. Ophthalmic Surg 1995; 26: 233-236.
58. Kass M, Meltzer D, Gordon M. A miniature compliance monitor for eyedrop medication. Arch Ophthalmol 1984; 102: 1550-1554.
59. Reardon G, Schwartz G, Mozaffari E, e. Patient persistency with pharmacotherapy in the management of glaucoma. Eur J Ophthalmol 2003; 13(Suppl 4): 52.
60. Diestelhorst M, Schaefer C, Beusterien K, Plante K, Fain J, Mozaffari E et al. Persistency and clinical outcomes associated with latanoprost and beta-blocker monotherapy: evidence from a European retrospective cohort study. Eur J Ophthalmol 2003; 13(Suppl 4): S21-9.
61. Beck AD, Grossniklaus HE, Hubbard B, Saperstein D, Haupert CL, Margo CE. Pathologic findings in late endophthalmitis after glaucoma filtering surgery. Ophthalmology 2000; 107: 2111-2114.
62. Freedman J, Gupta M, Bunke A. Endophthalmitis after trabeculectomy. Arch Ophthalmol 1978; 96: 1017-1018.
63. Krzystolik MG, Ciulla TA, Topping TM, Baker AS. Exogenous Aspergillus niger endophthalmitis in a patient with a filtering bleb. Retina 1997; 17: 461-462.
64. Higginbotham EJ, Stevens RK, Musch DC, Karp KO, Lichter PR, Bergstrom TJ et al. Bleb-related endophthalmitis after trabeculectomy with mitomycin C. Ophthalmology 1996; 103: 650-656.
65. Freedman SF, McCormick K, Cox TA. Mitomycin C-augmented trabeculectomy with postoperative wound modulation in pediatric glaucoma. J AAPOS 1999; 3: 117-124.
66. Mandal AK, Bagga H, Nutheti R, Gothwal VK, Nanda AK. Trabeculectomy with or without mitomycin-C for paediatric glaucoma in aphakia and pseudophakia following congenital cataract surgery. Eye 2003; 17: 53-62.
67. Azuara-Blanco A, Katz LJ. Dysfunctional filtering blebs. Surv Ophthalmol 1998; 43: 93-126.
68. Ayyala RS, Bellows AR, Thomas JV, Hutchinson BT. Bleb infections: clinically different courses of 'blebitis' and endophthalmitis. Ophthalmic Surg Lasers 1997; 28: 452-460.
69. Kresloff MS, Castellarin AA, Zarbin MA. Endophthalmitis. Surv Ophthalmol 1998; 43: 193-224.
70. Wolner B, Liebmann JM, Sassani JW, Ritch R, Speaker M, Marmor M. Late bleb-related endophthalmitis after trabeculectomy with adjunctive 5-fluorouracil. Ophthalmology 1991; 98: 1053-1060.
71. Greenfield DS, Suner IJ, Miller MP, Kangas TA, Palmberg PF, Flynn HW, Jr. Endophthalmitis after filtering surgery with mitomycin. Arch Ophthalmol 1996; 114: 943-949.
72. Ishida M, Takeuchi S. Vitrectomy for the treatment of expulsive hemorrhage. Jpn J Ophthalmol 2000; 44: 571.
73. Tuli SS, WuDunn D, Ciulla TA, Cantor LB. Delayed suprachoroidal hemorrhage after glaucoma filtration procedures. Ophthalmology 2001; 108: 1808-1811.
74. Edmunds B, Thompson JR, Salmon JF, Wormald RP. The National Survey of Trabeculectomy. III. Early and late complications. Eye 2002; 16: 297-303.
75. Anderson D. Normal tension glaucoma study. Collaborative normal tension glaucoma study. Curr Opin Ophthalmol 2003; 14: 86-90.
76. Shaarawy T, Karlen M, Schnyder C, Achache F, Sanchez E, Mermoud A. Five-year results of deep sclerectomy with collagen implant. J Cataract Refract Surg 2001; 27: 1770-1778.
77. Ambresin A, Borruat FX, Mermoud A. Recurrent transient visual loss after deep sclerectomy. Arch Ophthalmol 2001; 119: 1213-1215.
78. Chiselita D. Non-penetrating deep sclerectomy versus trabeculectomy in primary open- angle glaucoma surgery. Eye 2001; 15: 197-201.
79. El Sayyad F, Helal M, El-Kholify H, Khalil M, El-Maghraby A. Nonpenetrating deep sclerectomy versus trabeculectomy in bilateral primary open-angle glaucoma. Ophthalmology 2000; 107: 1671-1674.
80. Gandolfi S, Cimino L. Deep sclerectomy without absorbable implants and with unsutured scleral flap: prospective, randomized 2-year clinical trial vs trabeculectomy with releasable sutures. Conference Proceedings. Fort Lauderdale, USA, 2000.
81. Mermoud A, Schnyder CC, Sickenberg M, Chiou AG, Hediguer SE, Faggioni R. Comparison of deep sclerectomy with collagen implant and trabeculectomy in open-angle glaucoma. J Cataract Refract Surg 1999; 25: 323-331.
82. Carassa R. Viscocanalaostomy versus trabeculectomy: a 12 months prospective randomized study. Conference Proceedings. Boston, USA, 2000.
83. O'Brart DP, Rowlands E, Islam N, Noury AM. A randomised, prospective study comparing trabeculectomy augmented with antimetabolites with a viscocanalostomy technique for the management of open angle glaucoma uncontrolled by medical therapy. Br J Ophthalmol 2002; 86: 748-754.
84. Gordon MO, Beiser JA, Brandt JD, Heuer DK, Higginbotham EJ, Johnson CA et al. The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol 2002; 120: 714-720.
85. Cvenkel B, Ihan A. Ocular surface changes induced by topical antiglaucoma monotherapy. Ophthalmologica 2002; 216: 175-179.
86. Costagliola C, Prete AD, Incorvaia C, Fusco R, Parmeggiani F, Di Giovanni A. Ocular surface changes induced by topical application of latanoprost and timolol: a short-term study in glaucomatous patients with and without allergic conjunctivitis. Graefes Arch Clin Exp Ophthalmol 2001; 239: 809-814.
87. Watson PG, Jakeman C, Ozturk M. The complications of trabeculectomy (a 20-year follow-up). Eye 1990; 4: 425-438.
88. Molteno A, Bosma N, Kittelson J. Otago glaucoma surgery outcome study: long-term results of trabeculectomy-1976 to 1995. Ophthalmology 2003; 106: 1742-1750.
89. Broadway D, Grierson I, O'Brien C, Hitchings R. Adverse effects of topical antiglaucoma medications. II. The outcome of filtration surgery. Arch Ophthalmol 1994; 112: 1446-1454.
90. Kansal S, Moster MR, Gomes MC, Schmidt Jr CM, Wilson RP. Patient comfort with combined anterior sub-Tenon's, topical, and intracameral anesthesia versus retrobulbar anesthesia in trabeculectomy, phacotrabeculectomy, and aqueous shunt surgery. Ophthalmic Surg Lasers 2002; 33: 456-462.
91. Sauder G, Jonas JB. Topical anesthesia for penetrating trabeculectomy. Graefes Arch Clin Exp Ophthalmol 2002; 240: 739-742.
92. Vicary D, McLennan S, Sun XY. Topical plus subconjunctival anesthesia for phacotrabeculectomy: one year follow-up. J Cataract Refract Surg 1998; 24: 1247-1251.
93. Farrell TA. Minimizing the systemic effects of glaucoma medications. Geriatrics 1991; 46, 61-64, 73.
94. Fraunfelder FT, Meyer SM. Systemic side effects from ophthalmic timolol and their prevention. J Ocul Pharmacol 1987; 3: 177-184.
95. Bourgeois JA. Depression and topical ophthalmic beta adrenergic blockade. J Am Optom Assoc 1991; 62: 403-406.
96. Waldock A, Snape J, Graham CM. Effects of glaucoma medications on the cardiorespiratory and intraocular pressure status of newly diagnosed glaucoma patients. Br J Ophthalmol 2000; 84: 710-713.
97. Leibowitz HM, Krueger DE, Maunder LR, Milton RC, Kini MM, Kahn HA et al. The Framingham Eye Study monograph: an ophthalmological and epidemiological study of cataract, glaucoma, diabetic retinopathy, macular degeneration, and visual acuity in a general population of 2631 adults, 1973-1975. Surv Ophthalmol 1980; 24: 335-610.
98. Burrows B, Barbee RA, Cline MG, Knudson RJ, Lebowitz MD. Characteristics of asthma among elderly adults in a sample of the general population. Chest 1991; 100: 935-942.
99. Kaiser HJ, Flammer J, Stumpfig D, Hendrickson P. Longterm visual field follow-up of glaucoma patients treated with beta- blockers. Surv Ophthalmol 1994; 38(Suppl): S156-S159.
100. Orzalesi N, Rossetti I, Bottoli A, Invernizzi T, Fumagalli E, Fogagnolo P. Comparison of latanoprost, brimonidine and a fixed combination of timolol and dorzolamide on circadian intraocular pressure in patients with primary open-angle glaucoma and ocular hypertension. Acta Ophthalmol Scand Suppl 2002; 236: 55.
101. Arieta C, Amaral M, Matuda E, Crosta C, Carvalho Moreira FD, Jose N. Dorzolamide x Apraclonidine in the prevention of the intraocular pressure spike after Nd:YAG laser posterior capsulotomy. Curr Eye Res 2002; 25: 237-241.
102. Day DG, Schacknow PN, Wand M, Sharpe ED, Stewart JA, Leech J et al. Timolol 0.5% / dorzolamide 2% fixed combination vs timolol maleate 0.5% and unoprostone 0.15% given twice daily to patients with primary open-angle glaucoma or ocular hypertension. Am J Ophthalmol 2003; 135: 138-143.
103. Honrubia FM, Larsson LI, Spiegel D. A comparison of the effects on intraocular pressure of latanoprost 0.005% and the fixed combination of dorzolamide 2% and timolol 0.5% in patients with open-angle glaucoma. Acta Ophthalmol Scand 2002; 80: 635-641.
104. Simmons ST. Efficacy of brimonidine 0.2% and dorzolamide 2% as adjunctive therapy to beta-blockers in adult patients with glaucoma or ocular hypertension. Clin Ther 2001; 23: 604-619.
105. Strohmaier K, Snyder E, DuBiner H, Adamsons I. The efficacy and safety of the dorzolamide-timolol combination versus the concomitant administration of its components. Dorzolamide-Timolol Study Group. Ophthalmology 1998; 105: 1936-1944.
106. Strahlman E, Tipping R, Vogel R. A six-week dose-response study of the ocular hypotensive effect of dorzolamide with a one-year extension. Dorzolamide Dose-Response Study Group. Am J Ophthalmol 1996; 22(2): 183-194.
107. Vold SD, Riggs WL, Jackimiec J. Cost analysis of glaucoma medications: a 3-year review. J Glaucoma 2002; 11: 354-358.
108. Vold SD, Wiggins DA, Jackimiec J. Cost analysis of glaucoma medications. J Glaucoma 2000; 9: 150-153.
109. Kobelt G. Health economics, economic evaluation, and glaucoma. J Glaucoma 2003; 11: 531-539.
110. Gandolfi S, Quaranta L, Cimino L, Bettelli S. Deep sclerectomy versus trabeculectomy. Prospective Randomized Clinical trial. 4-year interim analysis. Proceedings of the Second International Congress on Glaucoma Surgery. Luxor, Egypt, 2003.